Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials - Wikidata - wikimedia - TriplyDB

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

http://www.wikidata.org/entity/Q28237583

about

The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD Exercise training in idiopathic pulmonary fibrosis: is it of benefit?Therapeutic Approach to Adult Fibrotic Lung Diseases Cardiac manifestations of idiopathic pulmonary fibrosis Pharmacological management of IPF Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis New perspectives on management of idiopathic pulmonary fibrosis Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Lung transplantation in IIP: A review Medical Therapy of Fibrostenotic Crohn's Disease Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis Clinical trials of investigational agents for IPF: a review of a Cochrane report Acute and subacute idiopathic interstitial pneumonias Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis Cell-based therapy in lung regenerative medicine Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers IPF clinical trial design and endpoints Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis Fibrotic and sclerotic manifestations of chronic graft-versus-host disease Smoking-related interstitial lung disease Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment.Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges Molecular mechanism and treatment of viral hepatitis-related liver fibrosis.Idiopathic Pulmonary Fibrosis: Treatment and Prognosis Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis Update on diagnosis and treatment of idiopathic pulmonary fibrosis Update on therapeutic management of idiopathic pulmonary fibrosis Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease UK asbestos imports and mortality due to idiopathic pulmonary fibrosis Pleural inhibition of the caspase-1/IL-1β pathway diminishes profibrotic lung toxicity of bleomycin Epidemiology and management of common pulmonary diseases in older persons Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials

P2860

Q21195756-686A6191-88DC-4E2B-8309-20BFBA02430D Q26738458-94AAC54E-C43A-4210-AD7F-44F83E4CC0B1 Q26740540-59CD3B74-5AF1-46E6-94BB-6C22BCCD126B Q26740857-EB2E753F-8C31-4DF7-9C2C-AC95105759A7 Q26741569-474223C5-5A85-439E-8E07-052EC7EEFE90 Q26748176-6540B8F1-CB51-410D-8EBE-880F60273C73 Q26748808-E0187206-F70A-4F06-A286-464AE3263840 Q26750418-0E5DCECE-05F2-4201-9A9A-987C62BBD47C Q26765586-C1E73423-353E-4844-8600-F87F062B2CD5 Q26771309-9ADA31EF-7D33-40A5-A64C-1682661E1DC9 Q26771647-D0A8530E-12E7-4BB1-BBF2-8CFCE19DDEA7 Q26773161-8C8D5877-5A61-47ED-810A-CEE6F9F45652 Q26774870-9FFC7A89-DFEC-4B03-934D-B729335D0B55 Q26777724-D97E259C-BBD4-4256-A134-9554CC318CA6 Q26777928-29C8B701-C922-4E43-BD6C-2F31F439BA87 Q26781255-106848A2-45FB-41DD-87EE-7EE1A3C4E46C Q26783169-FB4B8A91-04AA-4F9C-A521-C15EF452BD9B Q26797272-0C53D0FE-1080-44A3-8DDC-B4C1662FE25E Q26823161-E7050BC0-42AB-41C9-B736-D71ED97813D5 Q26824327-A9601D76-456A-4F87-A881-40DD79C20DA1 Q26824810-B3FDF9AE-1836-4B0B-AF86-8DC91006CADB Q26849378-510A7D68-3162-496B-A682-B9217B336EA6 Q26852285-67E92B16-799A-4C51-A78D-798D6B986BDF Q26864836-CF2AF621-5C0B-4567-BF50-2444B7B4AC12 Q26995648-0307785F-6087-4BB3-AC91-5743E4AB1BEA Q27003892-1625D315-A032-47E0-93E5-0388739910A2 Q27024147-F21B5DDE-F0C7-494C-AC38-6321F5DA89BF Q27027779-93F9C413-29BF-4398-AD30-EEC80228FF73 Q27309770-DED613D0-A98B-45EB-95E3-030D68DB4C25 Q27499290-3330C1C4-8863-416F-854D-9260CB915DC7 Q27692609-6616528E-952B-4A7D-B535-F77FF9533148 Q28073641-873ECC82-3144-4A8C-A3B3-61D558A2B2B1 Q28075536-422CD86B-A693-4767-B859-9300A7AC71A0 Q28083702-BCE8133D-7DF9-4DA0-8973-BA6DF817B73A Q28083944-E3CD57EF-E36A-4469-BF19-DC8B8DF2AF27 Q28085094-3D0E5FA8-96CC-42D5-BC73-87D1CE207650 Q28387325-E40240DC-42C3-4E5D-9C58-91B5F7D5DCEF Q28395139-7B932E8E-0735-4C73-8100-B398111E56CE Q28397465-91225632-EBE4-40BC-AB34-0730C7002DD9 Q28484304-E1E41CEE-BA6A-43EF-90F3-FB37E750BBC1

P2860

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

http://www.wikidata.org/entity/Q28237583

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pirfenidone in patients with i ...... PACITY): two randomised trials

@ast

Pirfenidone in patients with i ...... PACITY): two randomised trials

@en

Pirfenidone in patients with i ...... PACITY): two randomised trials

@nl

type

label

Pirfenidone in patients with i ...... PACITY): two randomised trials

@ast

Pirfenidone in patients with i ...... PACITY): two randomised trials

@en

Pirfenidone in patients with i ...... PACITY): two randomised trials

@nl

prefLabel

Pirfenidone in patients with i ...... PACITY): two randomised trials

@ast

Pirfenidone in patients with i ...... PACITY): two randomised trials

@en

Pirfenidone in patients with i ...... PACITY): two randomised trials

@nl

P1433

Q28237583-B72298C0-E939-4069-A937-57F315FA4B8E

P1476

Q28237583-689A1110-5295-42B3-B8C6-082425E25E17

P2093

Q28237583-0ACD9E09-8852-401D-B391-5997EFD73855

Q28237583-2DAD8523-6C94-4B8F-8032-476B74486D63

Q28237583-43009D47-3904-4F22-BC76-441AC78F21B5

Q28237583-53196F08-FD71-4903-936D-42FE31D7A1D5

Q28237583-5513E43D-2209-435C-AB14-BD9B20F1808A

Q28237583-6AD3B2AA-3FCE-4C83-BD24-07D4DD6259D7

Q28237583-7247CEC0-721A-4681-97E1-0E77F5B0CDA1

Q28237583-870FD400-F081-453B-9796-DB9208468B5E

Q28237583-E384C285-C30C-43C8-B2F7-92DD9C714F9F

Q28237583-EC3DB01B-7A87-41A7-90C7-AE064D8C754D

P304

Q28237583-263C971D-59CB-4138-96BF-85768E69A828

P31

Q28237583-5596687A-1BEE-4250-B082-F7B7BDE89D6E

P3181

Q28237583-6B57EBF9-5068-4633-9CB2-1E86BC8FA9C2

P356

Q28237583-85415837-5640-4153-BE72-B73001216E1C

P407

Q28237583-F4332A11-A35F-4D56-9E37-DFEC6AA21148

P433

Q28237583-181C4524-AC0A-4D8B-9D5E-1F5F533973CE

P478

Q28237583-08867E6C-D5D3-4C34-96C0-859F277BAE58

P50

Q28237583-8B21C877-B843-44B8-8C91-5DB4B5FFAE24

P577

Q28237583-A1FC1DCC-ACB1-45B5-AEF7-BB209593D39E

P698

Q28237583-6B8515AB-684B-46AA-B299-26C5102AD770

P921

Q28237583-0D5D3C55-7500-4FCF-B801-8AB4C08BE3A4

Q28237583-32831F7F-DE9B-4913-BCA6-0B4B8C115FC3

P3181

P356

S0140-6736(11)60405-4

P1433

P1476

Pirfenidone in patients with i ...... PACITY): two randomised trials

@en

P2093

Carlo Albera

http://www.w3.org/2001/XMLSchema#string

David Kardatzke

http://www.w3.org/2001/XMLSchema#string

Dominique Valeyre

http://www.w3.org/2001/XMLSchema#string

Javier Szwarcberg

http://www.w3.org/2001/XMLSchema#string

Lisa Lancaster

http://www.w3.org/2001/XMLSchema#string

Marilyn K Glassberg

http://www.w3.org/2001/XMLSchema#string

Paul W Noble

http://www.w3.org/2001/XMLSchema#string

Roland M du Bois

http://www.w3.org/2001/XMLSchema#string

Steven A Sahn

http://www.w3.org/2001/XMLSchema#string

Talmadge E King

http://www.w3.org/2001/XMLSchema#string

P304

1760-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

10785

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(11)60405-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

9779

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

Ulrich Costabel

P577

2011-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21571362

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis